Table 2.
Author, year | Country /Region |
Study design | Case (n) | Treatment | Sample | Detection method | Cytokine detected | Cytokine with significant difference after treatment |
---|---|---|---|---|---|---|---|---|
Elamrousy et al., 202118 | Egypt | Randomized controlled | 20 | Topical camel whey protein | Serum | Flow cytometry | IL-1, IL-6, TNF-α | IL-1, IL-6, TNF-α |
Han et al., 20214 | China | Comparative study | 80 | Not reported | Plasma | ELISA | IL-1β, IL-2, TNF-α | IL-1β, IL-2, TNF-α |
Lu et al., 20205 | China | Comparative study | 60 | Systemic thalidomide | Plasma | ELISA | IL-6, IL-18 | IL-6, IL-18 |
Mimura et al., 20176 | Brazil | Randomized controlled | 22 | Systemic symbiotic | Serum | MAP Human Cytokine/Chemokine Magnetic Bead | IL-4, IL-6, IL-10, IL-12p70, IL-17A, TNF-α | IL-4, TNF-α |
Gupta et al., 20149 | India | Comparative study | 30 | Systemic levamisole | Serum | ELISA | IL-8 | IL-8 |
Sun et al., 200613 | China, Taiwan | Comparative study | 55 | Systemic levamisole | Serum | ELISA | TNF-α | TNF-α |
Sun et al., 200519 | China, Taiwan | Comparative study | 19 | Systemic Tien-Hsien liquid | Serum | ELISA | IL-2, IL-6, IL-10, TNF-α, IFN-γ | IL-2, IL-6, TNF-α, IFN-γ |
Sun et al., 200416 | China, Taiwan | Comparative study | 82 | Systemic levamisole | Serum | Immulite assay | IL-6, IL-8 | IL-6, IL-8 |
Sun et al., 20033 | China, Taiwan | Comparative study | 45 | Systemic levamisole and Chinese medicinal herbs | Serum | Immulite assay | IL-6 | IL-6 |
Abbreviations: ELISA, enzyme-linked immunosorbent assay; IFN, interferon; IL, interleukin; TGF, transforming growth factor; TNF, tumor necrosis factor.